ReviewClinical reviews in allergy & immunology2007
The Heart and APS.
Review in Clinical reviews in allergy & immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.Clinical reviews in allergy & immunology · 2013Pooled it
- Hypothyroidism and Double Mitral Lesion in Antiphospholipid Syndrome During Pregnancy: A Case Report.The American journal of case reports · 2025Article
- Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature.Clinical rheumatology · 2023Review
- SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis.Clinical rheumatology · 2023Review
- Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome.Mediterranean journal of rheumatology · 2018Article
- Cardiac manifestations of rheumatological conditions: a narrative review.ISRN rheumatology · 2012Article
- Left-sided cardiac valvulitis in tristetraprolin-deficient mice: the role of tumor necrosis factor alpha.The American journal of pathology · 2010Article
- Patients' experiences of a diagnosis of Hughes' syndrome.Clinical rheumatology · 2009Article
- Vasculitis: current status and future directions.Clinical reviews in allergy & immunology · 2008Article
- Cutting edge issues in autoimmunity.Clinical reviews in allergy & immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heart is a target organ in antiphospholipid syndrome (APS). Endocardial disease, intracardiac thrombosis, myocardial involvement including coronary heart disease and microvascular thrombosis, as well as pulmonary hypertension have all been described in APS patients. Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic. Anticoagulant/antiplatelet treatment is ineffective in terms of valvular lesion regression. Some patients require cardiac valve replacement. However, patients with APS have shown an increased perioperative morbidity and mortality. Intracardiac thrombosis, although a rare complication, can cause pulmonary and systemic emboli. Differential diagnosis with myxoma may be very difficult.
Indexed as
Identifiers
17916990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.